



US NANOTECHNOLOGY LEADER JOINS DNT BOARD

MELBOURNE, 16 DECEMBER 2003: Starpharma Pooled Development Limited (ASX:SPL) is pleased to announce that Prof Jean Fréchet has joined the Board of Dendritic Nanotechnologies, Inc. (DNT), the US nanotechnology company in which Starpharma has a 49.9% equity interest.

Starpharma CEO Dr John Raff said: "Prof Fréchet has outstanding scientific credentials in addition to extensive experience and involvement in commercial and venture capital areas. His appointment to the Board of DNT complements other recent high profile commercial appointments, and further consolidates DNT as a significant participant in the US nanotechnology industry."

Prof Fréchet is an advisor to a number of the world's leading technology and chemical companies and is an international leader in the area of nanotechnology. He is also Professor of Chemistry at the University of California Berkeley campus.

His research at the interface of organic and polymer chemistry is in the broad area of nanoscience and nanotechnology, and is directed towards functional macromolecules, their design, synthesis, and applications. Current topics include new synthetic approaches to macromolecules with controlled architecture, engineered polymer systems and molecular machines, the design synthesis, and applications of dendritic and other functional polymers, novel imaging materials for nanoscale lithography, energy harvesting and conversion, catalysis with dendrimers as enzyme mimics, polymers in separation and molecular recognition, combinatorial approaches to new materials, biosensing, and functional macromolecules in targeted drug, vaccine, and DNA delivery.

Jean Fréchet is the co-author of approximately 600 publications and 60 issued patents, several of which are exploited commercially. He is currently in Australia at the invitation of Starpharma providing scientific and strategic advice.

Starpharma Pooled Development Limited (ASX:SPL) is a registered pooled development fund with investments in wholly owned subsidiary biopharmaceutical companies focused on the development and application of dendrimer nanotechnologies as drugs against major diseases. Starpharma's lead dendrimer product, VivaGel™ has received clearance from the US FDA for human clinical trials. VivaGel™ is a topical microbicide gel product that has been developed for women as a preventative against the sexual transmission of HIV.

CONTACTS:

Dr John Raff
Chief Executive Officer
+61 3 8532 2701
www.starpharma.com

Mr Ben Rogers
Company Secretary
+61 3 8532 2702